Kryxana 200mg Tablet

Most side effects of Kryxana 200mg Tablet do not require medical attention as they may disappear as your body adjusts to the medicine. In case these side effects become worse, consult your doctor immediately. Following are the side effects:

• Fatigue and tiredness
• Headache and dizziness (including vertigo or fainting)
• Nausea, vomiting, diarrhea, or constipation
• Abdominal pain
• Rash, itching, or skin changes
• Hair thinning or loss
• Cough, breathlessness, or nasal inflammation
• Fever and night sweats
• Trouble sleeping (insomnia)
• Back or joint pain, muscle cramps
• Swelling in the face, legs, ankles, or feet (edema) with weight gain
• Increased tearing (watery eyes) or dry eyes
• Reduced appetite
• Changes in blood counts (low red cells, white cells, or platelets)
• Infections
• Elevated liver enzymes or creatinine levels
• Low calcium, potassium, or blood sugar (especially with insulin or sulphonylureas)
• Severe neutropenia (very low white blood cell counts)
• Hepatobiliary toxicity (serious liver problems or liver failure)
• Heart failure or prolonged QT interval (abnormal heart rhythm)
• Gastrointestinal disorders
• Hypothyroidism
• Pneumonitis or interstitial lung disease
• Generalized swelling in the body

• Take Kryxana 200mg Tablet in exact dose as prescribed by the doctor.
• The typical dose of this tablet varies with age, type & stage of the cancer, and overall health factor of the patient.
• It can be taken with or without food but at a fixed time each day to get better results.
• Ribociclib Tablet should be swallowed as a whole with water without crushing, chewing, or opening the capsule.
• Don't miss a dose or overdose the medicine.

• Kryxana 200mg Tablet is an anticancer medicine with active ingredient Ribociclib (200mg). It belongs to a group of cancer-fighting medications known as antineoplastics.
• This tablet works by blocking the action of the kinase protein, which is important for the growth and division of cells. As a result, it slows the progression of cancer.

• If a dosage is skipped or vomiting occurs after administration of the tablet, just skip the missed dose and keep on with the next scheduled one; however, never take a double dose.
• The tablet is supposed to be taken once a day, either with or without meals, but at the same time every day in order to prevent missing a dose.
• It is important to use effective birth control measures to avoid getting pregnant while on this treatment.
• Make sure to notify your physician about your condition in case you are pregnant, want to become pregnant, or are nursing a child.
• As the tablet may cause dizziness, do not drive or perform tasks that require clear thinking until its effects are determined.
• Blood testings can be done on a frequent basis in order to check the state of your liver and blood count.
  

• Abdelmalak, M., Singh, R., Anwer, M., et al. (2022). The renaissance of CDK inhibitors in breast cancer therapy: An update on clinical trials and therapy resistance. Cancers, 14(21), 5388 - https://pubmed.ncbi.nlm.nih.gov/36358806/
  
• Dajsakdipon, T., Susiriwatananont, T., Wongkraisri, C., Ithimakin, S., Parinyanitikul, N., Supavavej, A., & TSCO Breast Oncology Group. (2024). Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus aromatase inhibitor in HR+/HER2− advanced breast cancer: Preliminary real‑world data from Thailand. BMC Cancer, 24(1), 1018 - https://link.springer.com/article/10.1186/s12885-024-12765-x
  
• Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., … Goetz, M. P. (2022). Overall survival with ribociclib plus letrozole in advanced breast cancer. New England Journal of Medicine, 386(18), 942–950 - https://pubmed.ncbi.nlm.nih.gov/35263519/
  
• Ji, Y., Yartsev, V., Quinlan, M., Serra, P., Wang, Y., Chakraborty, A., & Miller, M. (2023). Justifying ribociclib dose in patients with advanced breast cancer with renal impairment based on PK, safety, and efficacy data: An innovative approach integrating data from a dedicated renal impairment study and oncology clinical trials. Clinical Pharmacokinetics, 62(3), 493–504 - https://pubmed.ncbi.nlm.nih.gov/36800111/
  
• Xu, J., Wang, R., & Shen, K. (2025). A post-marketing disproportionality analysis of the safety of ribociclib based on the FDA Adverse Event Reporting System. Therapeutic Advances in Drug Safety, 16, 20420986251324633 - https://pmc.ncbi.nlm.nih.gov/articles/PMC11869255/